Aziz Rahman, MD
Pulmonary Disease · Centralia, ILNPI 1275540015
Payments from drug & device makers
Across 75 payments — averaging $17.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$432
- Sanofi-aventis U.S. LLC$138
- Spinal Elements, Inc.$131
- Sunovion Pharmaceuticals Inc.$127
- Takeda Pharmaceuticals U.S.A., Inc.$108
- Astellas Pharma US Inc$80
- plus $276 from 13 others
What the payments were for
- Food & beverage$1,04481%
- Education$24719%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 29 | $432 |
| Sanofi-aventis U.S. LLC | 2 | $138 |
| Spinal Elements, Inc. | 1 | $131 |
| Sunovion Pharmaceuticals Inc. | 14 | $127 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $108 |
| Astellas Pharma US Inc | 1 | $80 |
| Novartis | 3 | $47 |
| Pfizer | 3 | $43 |
| Sumitomo Pharma America, Inc. | 2 | $26 |
| Actelion Pharmaceuticals US, Inc. | 2 | $25 |
| Electromed, Inc. | 1 | $20 |
| Baxter Healthcare | 1 | $18 |
| CSL Behring | 1 | $17 |
| GSK | 1 | $16 |
| Optinose US, Inc. | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $12 |
| Boehringer Ingelheim | 1 | $12 |
| Genentech USA, Inc. | 1 | $12 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Medical Devices$262
How this compares
$1,291 in reported general payments places this provider in the 45th percentile of 539 pulmonary disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 369 | $301,223 |
| OfevNintedanib Esylate | 16 | $217,646 |
| EliquisApixaban | 243 | $146,637 |
| FarxigaDapagliflozin Propanediol | 176 | $144,794 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 165 | $134,199 |
| JardianceEmpagliflozin | 149 | $117,362 |
| OzempicSemaglutide | 84 | $93,925 |
| Spiriva RespimatTiotropium Bromide | 108 | $89,830 |
| MounjaroTirzepatide | 67 | $88,437 |
| Dupixent PenDupilumab | 20 | $83,955 |
| Fasenra PenBenralizumab | 14 | $80,891 |
| Dupixent SyringeDupilumab | 19 | $74,260 |
| EntrestoSacubitril/Valsartan | 87 | $65,156 |
| XareltoRivaroxaban | 86 | $58,661 |
| NucalaMepolizumab | 13 | $56,052 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Jardiance, Spiriva Respimat, Stiolto Respimat, Tradjenta | $12 | $467,380330 claims |
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Incruse Ellipta, Anoro Ellipta | $16 | $415,056491 claims |
| PfizerEliquis | $43 | $146,637243 claims |
| NovartisEntresto | $47 | $65,15687 claims |
| Johnson & JohnsonXarelto | $12 | $58,66186 claims |
| AbbVieLinzess, Vraylar | $432 | $50,77364 claims |
| Astellas Pharma US IncMyrbetriq | $80 | $35,66673 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 539 pulmonary disease providers in Illinois.
Other pulmonary disease in Centralia
- Douglas HogarthChicago$3.1M
- Manu JainChicago$1.9M
- Momen WahidiChicago$1.2M
- Shashi BellamEvanston$1.2M
- Marilyn GlassbergMaywood$1000K
- Steven WhiteChicago$989K
- Ravi KalhanChicago$831K
- Patrick WhittenPeoria$812K
- Jane Dematte DamicoChicago$811K
- Septimiu MurguChicago$804K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.